# US 2023/0265146 A1 · Cytokine conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265146 A1
- Document ID: US20230265146A1
- Status: Published application
- Kind: A1
- Application number: 18/073,935
- Filed: 2022-12-02
- Published: 2023-08-24
- Earliest claimed: 2020-06-25
- Assignees: Amunix Pharmaceuticals, Inc.
- Applicants: Amunix Pharmaceuticals, Inc.
- Inventors: Volker SCHELLENBERGER; Eric JOHANSEN; Angela HENKENSIEFKEN; Bryan IRVING; Tracy YOUNG; Vibha CHAUHAN; Valentine YEUNG
- Web page: https://patentgrep.com/patent/US20230265146A1

## CPC

- C07K 14/5434: {IL-12}
- A61P 35/00: Antineoplastic agents
- C07K 14/001: {by chemical synthesis}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions comprising biologically active proteins, such as cytokines, linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of related disorders and conditions.

## Claims

### Claim 1

A fusion protein comprising:
(a) an extended recombinant polypeptide characterized in that:
i) it comprises at least 12 amino acid residues;
ii) at least 90% of the amino acid residues of the extended recombinant polypeptide are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P); and
iii) it has 4-6 different amino acid residues selected from G, A, S, T, E and P;
(b) a cytokine; and
(c) a linker joining the cytokine and the extended recombinant polypeptide, wherein the linker comprises a release segment (RS).

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein said fusion protein comprises 1, 2, 3, 4 or more extended recombinant polypeptides.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein said fusion protein further comprises a tumor targeting domain.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein said RS is capable of being cleaved by at least one mammalian protease.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein has a structural arrangement, from N- to C-terminus of XTEN-RS-cytokine or cytokine-RS-XTEN.

### Claim 9 (depends on 1)

The fusion protein of claim 1, wherein the cytokine is selected from a group consisting of interleukins, chemokines, interferons, tumor necrosis factors, colony-stimulating factors, or TGF-Beta superfamily members.

### Claim at position 8

10-11. (canceled)

### Claim 12 (depends on 9)

The fusion protein of claim 9, wherein the cytokine is IL-12 or an IL-12 variant.

### Claim 13 (depends on 1)

The fusion protein of claim 1, wherein the cytokine comprises a first cytokine fragment (Cy1) and a second cytokine fragment (Cy2).

### Claim 14 (depends on 13)

The fusion protein of claim 13, wherein Cy1 comprises an IL-12 p35 subunit.

### Claim 15 (depends on 14)

The fusion protein of claim 14, wherein Cy2 comprises an IL-12 p40 subunit sequence identity to an interleukin-12 subunit alpha.

### Claim at position 13

16-17. (canceled)

### Claim 18 (depends on 13)

The fusion protein of claim 13, wherein the cytokine comprises a linker positioned between the first cytokine fragment (Cy1) and the second cytokine fragment (Cy2).

### Claim 19 (depends on 18)

The fusion protein of claim 18 wherein said fusion protein comprises a Cy1 fragment that comprises an extended recombinant polypeptide at the N terminus and an extended recombinant polypeptide at the C-terminus.

### Claim 20 (depends on 18)

The fusion protein of claim 18 wherein said fusion protein comprises a Cy2 fragment that comprises an extended recombinant polypeptide at the N terminus and an extended recombinant polypeptide at the C-terminus.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The fusion protein of claim 1, wherein the extended recombinant polypeptide sequence consists of multiple non-overlapping sequence motifs, wherein the sequence motifs are selected from the sequence motifs of Table 1.

### Claim at position 19

23-27. (canceled)

### Claim 28 (depends on 1)

A pharmaceutical composition, comprising the fusion protein of claim 1 and at least one pharmaceutically acceptable carrier.

### Claim at position 21

29-30. (canceled)

### Claim 31 (depends on 1)

A method of treating or preventing a disease or condition in a subject, the method comprising administering to a subject a therapeutically effective amount of the fusion protein of claim 1.

### Claim at position 23

32-34. (canceled)

### Claim 35

A fusion protein comprising a disulfide-linked heterodimer,
wherein the disulfide-linked heterodimer comprises a first subunit and a second subunit,
wherein the first subunit comprises the following elements in a N-to-C terminal or a C-to-N terminal orientation:
(a) an extended recombinant polypeptide characterized in that:
i) it comprises at least 12 amino acid residues;
ii) at least 90% of the amino acid residues of the extended recombinant polypeptide are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P); and
iii) it has 4-6 different amino acid residues selected from G, A, S, T, E and P;
(b) a release segment (RS); and
(c) a first cytokine fragment (Cy1);
wherein the second subunit comprises the following elements in a N-to-C terminal or a C-to-N terminal orientation:
(d) an extended recombinant polypeptide characterized in that:
i) it comprises at least 12 amino acid residues;
ii) at least 90% of the amino acid residues of the extended recombinant polypeptide are selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P); and
iii) it has 4-6 different amino acid residues selected from G, A, S, T, E and P;
(e) a release segment (RS); and
(f) a second cytokine fragment (Cy2).

### Claim 36 (depends on 35)

The fusion protein of claim 35, wherein Cy1 is an IL-12 p35 subunit.

### Claim 37 (depends on 35)

The fusion protein of claim 35, wherein Cy2 is an IL-12 p40 subunit.

### Claim 38

A kit comprising at least a first container, the first container comprising:
(a) an amount of a fusion protein sufficient to treat a disease, condition, or disorder upon administration to a subject in need thereof,
(b) an amount of a pharmaceutically acceptable carrier, together in a formulation ready for injection or for reconstitution with sterile water, buffer, or dextrose.

### Claim 39 (depends on 35)

The kit of claim 35, wherein the kit further comprises:
(a) a label identifying the fusion protein, storage and handling conditions,
(b) a sheet of the approved indications for the fusion protein,
(c) instructions for the reconstitution and/or administration of the fusion protein for the use for the prevention and/or treatment of an approved indication,
(d) appropriate dosage and safety information,
(e) information identifying the lot and expiration of the drug, or
(f) any combination of (a)-(e).
